5 mg + 325 mg clinical trials

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of iN1011-N17-02 in Patients with Post herpetic Neuralgia (PHN)

This study is testing a new medicine, iN1011-N17-02, for nerve pain after shingles. It aims to see if it's safe, how well it works, and what dose is best, compared to a dummy pill or other pain relief.